X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/inhibikase-therapeutics-announces-selection-of-the-bioequivalent-dose-of-ikt-001pro-and-provides-update-on-the-501-bioequivalence-study-301857483.html
https://www.globenewswire.com/news-release/2023/05/11/2666641/0/en/Aerami-Therapeutics-to-Present-Pharmacokinetic-Data-Supporting-AER-901-Inhaled-Imatinib-for-Pulmonary-Hypertension-at-the-2023-American-Thoracic-Society-ATS-International-Conferenc.html
https://www.globenewswire.com/news-release/2023/04/03/2639642/0/en/Aerami-Therapeutics-to-Host-Virtual-Investor-Day-with-Leading-Experts-in-Pulmonary-Hypertension-as-AER-901-Inhaled-Imatinib-Advances-Toward-Phase-2.html
https://www.globenewswire.com/news-release/2023/02/23/2614380/0/en/Aerami-Therapeutics-Announces-Expansion-of-the-AER-901-inhaled-imatinib-Development-Program-in-Pulmonary-Hypertension-Supported-by-Phase-1-Clinical-Trial-Data-and-Continued-Progres.html
https://www.fiercepharma.com/pharma/asco-takedas-iclusig-shows-potential-become-soc-phall
https://www.globenewswire.com//news-release/2022/12/21/2577846/0/en/Aerami-Therapeutics-Announces-Completion-of-Dosing-in-Phase-1-Trial-of-AER-901-inhaled-imatinib-a-Critical-Milestone-Toward-the-Planned-Initiation-of-a-Phase-2-Trial-in-Pulmonary-A.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212135
https://www.fiercepharma.com/pharma/asco-novartis-eyes-full-nod-gleevec-follow-scemblix-thanks-new-leukemia-data
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212135
http://www.pmlive.com/pharma_news/novartis_receives_approval_for_third-generation_leukaemia_therapy_1382889
https://www.fiercebiotech.com/biotech/daiichi-jettisons-adc-after-flunking-early-solid-tumor-test
https://endpts.com/two-decades-after-gleevec-approval-novartis-scores-new-cml-ok-for-wild-card-stamp-inhibitor/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-3-2021-1614760051.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-16-2020-1608097779.pdf
https://endpts.com/ash20-out-to-shake-up-cml-once-again-novartis-lays-out-head-to-head-between-third-gen-gleevec-scion-and-pfizer-rival/
https://endpts.com/novartis-finds-a-third-generation-scion-to-an-aging-gleevec-successfully-taking-on-a-pfizer-rival-for-last-chance-cml-patients/
https://www.globenewswire.com/news-release/2020/08/06/2074321/0/en/Aerovate-Therapeutics-Emerges-From-RA-Capital-Incubator-With-72-6-Million-Funding-for-Potential-Disease-Modifying-Pulmonary-Arterial-Hypertension-Therapy.html
https://endpts.com/ra-capital-backed-aerovate-launches-with-72-6m-to-treat-pah-with-a-repurposed-cancer-med/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212773
https://www.vectura.com/about/news/vectura-signs-agreement-with-aerami-therapeutics-inc/
https://www.globenewswire.com/news-release/2020/06/08/2044900/0/en/Aerami-Therapeutics-Signs-a-Global-License-Agreement-with-Vectura-Group-Adding-an-Inhaled-Therapy-for-Patients-with-Pulmonary-Arterial-Hypertension-to-Their-Pipeline.html
https://www.prnewswire.com/news-releases/fda-approves-first-drug-for-fourth-line-treatment-of-advanced-gastrointestinal-stromal-tumors-301060275.html
https://www.news-medical.net/news/20200511/AI-VIVO-seeks-pharma-biotech-collaboration-partners-to-advance-drug-candidates-for-COVID-19.aspx
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210658
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-usfda-nod-to-market-generic-cancer-drug/articleshow/75061780.cms
https://www.moneycontrol.com/news/business/stocks/cadila-healthcare-share-price-hits-52-week-high-on-usfda-nod-for-cancer-drug-5125901.html
https://www.moneycontrol.com/news/business/markets/shilpa-medicares-subsidiary-gets-uk-regulator-nod-for-anti-cancer-drug-5112971.html
https://www.reuters.com/article/us-china-health/china-expands-drug-bulk-buy-program-puts-pressure-on-pharma-firms-idUSKCN1VN0QS
https://www.biopharmadive.com/news/deciphera-gastrointestinal-cancer-drug-race-blueprint/560808/
https://www.fiercebiotech.com/biotech/deciphera-soars-as-phase-3-cancer-data-tee-up-fda-filing
https://www.prnewswire.com/news-releases/armas-pharmaceuticals-expands-generic-portfolio-with-launches-of-capecitabine-and-imatinib-300825348.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207818
https://www.reuters.com/article/us-column-miller-medicare/medicare-part-d-no-match-for-runaway-specialty-drug-costs-study-idUSKCN1PW16X
https://www.fiercebiotech.com/biotech/deciphera-cbo-morl-talks-lines-therapy-for-kinase-inhibitor-ripretinib
https://www.biopharmadive.com/news/blueprint-posts-impressive-data-for-lead-candidate-but-investor-response/542459/
https://www.gov.uk/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-september-2018
https://www.gov.uk/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-september-2018
https://www.gov.uk/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-september-2018
https://www.ema.europa.eu/documents/overview/imatinib-teva-bv-epar-summary-public_en-0.pdf
https://www.ema.europa.eu/documents/assessment-report/imatinib-teva-bv-epar-public-assessment-report_en-0.pdf
Market Place
Share 
